Ultralife Q4 revenue $44.5M (+23.4% YoY); adjusted EPS $0.18 vs -$0.03

ULTRALIFE CORP

2023-FY EPS reported $0.03 revenue$158,644,000

Q4 2023 sales $44.5M, up 23.4% YoY; full-year sales $158.6M, up 20.3%.
Q4 operating income $3.6M vs $0.2M; full-year $9.5M vs $0.1M.
Q4 adjusted EPS $0.18 vs loss of $0.03; full-year adjusted EPS $0.52 vs loss of $0.07.
Medical battery sales highest quarter ever; Battery & Energy gross margin expanded 360 bps to 25.2%.
Backlog $103.5M at year-end; management plans to pay down acquisition debt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ULTRALIFE CORP reported full year ended December 31, 2023 results: revenue $158.6 million, EPS Adjusted EPS of $0.52.

Period: full year ended December 31, 2023
Revenue: $158.6 million
EPS: Adjusted EPS of $0.52
Result: reported results

Exact text from the filing

representing a 134.8% year-over-year increase ● Backlog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: ● Sales of $158.6 million representing a 20.3% year-over-year increase ● Operating income of $9.5 million versus $0.1 million for 2022 ● Adjusted EPS of $0.52 compared to a loss of $0.07 for 2022 ●

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ULTRALIFE CORP reported fourth quarter ended December 31, 2023 results: revenue $44.5 million, net income $2.9 million, EPS $0.17 per diluted share.

Period: fourth quarter ended December 31, 2023
Revenue: $44.5 million
Net income: $2.9 million
EPS: $0.17 per diluted share
Result: reported results

Exact text from the filing

15, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: ● Sales of $44.5 million representing a 23.4% year-over-year increase ● Highest medical sales quarter in Company’s history ● Operating income of $3.6 million versus $0.2 million for the 2022 fourth

View on SEC.gov

460 earnings releases filed in the last 30 days. Browse all earnings releases →

ULTRALIFE CORP filing history →

Source: SEC EDGAR

accession 0001437749-24-004266

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.